
    
      This is a Phase I, open-label, parallel trial to evaluate Pharmacokinetics, Pharmacodynamics
      and Safety of Testosterone gel 1% for topic usage in post-menopausal women, Study
      participants will receive investigational product for 28 consecutive days, once daily, as per
      the following allocation: 2.2 mg, 4.4 mg. 8.8 mg or placebo.
    
  